📊 EXAS Key Takeaways
Is EXAS a Good Investment? Thesis Analysis
Exact Sciences demonstrates strong operational fundamentals with excellent gross margins (69.7%), positive free cash flow generation ($356.8M), and healthy balance sheet liquidity, but is currently unprofitable at the operating and net income levels despite stable revenue. The company's ability to convert high-margin revenue into sustainable profitability remains the critical question, though positive FCF and improving EPS trends suggest operational momentum.
Why Buy EXAS? Key Strengths
- Exceptional gross margin of 69.7% indicates strong pricing power and operational efficiency in core laboratory business
- Robust free cash flow of $356.8M with 11.0% FCF margin demonstrates ability to generate cash despite accounting losses
- Strong balance sheet with 2.43x current ratio, minimal debt burden (0.02x debt-to-equity), and $956M cash position providing financial flexibility
- Significant improvement in diluted EPS (-1.10 vs prior year performance) showing operational leverage and path toward profitability
- Active insider participation with 28 Form 4 filings in last 90 days suggesting management confidence
EXAS Investment Risks to Consider
- Negative operating margin (-6.4%) and net margin (-6.4%) indicate company is currently unprofitable despite generating revenue and positive cash flow
- Stagnant revenue growth (0.0% YoY) raises concerns about market saturation, competitive pressures, or execution challenges in core business
- Negative ROE (-8.7%) and ROA (-3.5%) signal inefficient capital deployment and value destruction from shareholder equity base
- Large gap between operating cash flow and net income suggests reliance on working capital management rather than sustainable profitability
- Negative interest coverage ratio (-6.3x) indicates insufficient operating earnings to service debt obligations
Key Metrics to Watch
- Operating margin trajectory toward profitability as leverage on fixed cost base improves
- Revenue growth acceleration as key inflection point given current 0% YoY stagnation
- Free cash flow sustainability and conversion rate as percentage of revenue
- SG&A expense reduction and operating expense management to drive toward EBITDA positivity
- Gross margin maintenance above 65% as pricing power indicator in competitive markets
EXAS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.43x current ratio provides a solid financial cushion.
EXAS Profitability Ratios
EXAS vs Healthcare Sector
How EXACT SCIENCES CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EXAS Overvalued or Undervalued?
Based on fundamental analysis, EXACT SCIENCES CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EXAS Balance Sheet & Liquidity
EXAS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: EXACT SCIENCES CORP's revenue has grown significantly by 118% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.13 indicates the company is currently unprofitable.
EXAS Growth Metrics (YoY)
EXAS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $708.7M | -$1.2M | $-0.10 |
| Q2 2025 | $699.3M | -$1.2M | $-0.01 |
| Q1 2025 | $637.5M | -$101.2M | $-0.54 |
| Q3 2024 | $628.3M | $794.0K | $0.00 |
| Q2 2024 | $622.1M | -$15.8M | $-0.09 |
| Q1 2024 | $602.5M | -$74.2M | N/A |
| Q1 2023 | $486.6M | $794.0K | $0.00 |
| Q3 2022 | $456.4M | -$31.2M | $-0.84 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EXAS Capital Allocation
EXAS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for EXACT SCIENCES CORP (CIK: 0001124140)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EXAS
What is the AI rating for EXAS?
EXACT SCIENCES CORP (EXAS) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EXAS's key strengths?
Claude: Exceptional gross margin of 69.7% indicates strong pricing power and operational efficiency in core laboratory business. Robust free cash flow of $356.8M with 11.0% FCF margin demonstrates ability to generate cash despite accounting losses.
What are the risks of investing in EXAS?
Claude: Negative operating margin (-6.4%) and net margin (-6.4%) indicate company is currently unprofitable despite generating revenue and positive cash flow. Stagnant revenue growth (0.0% YoY) raises concerns about market saturation, competitive pressures, or execution challenges in core business.
What is EXAS's revenue and growth?
EXACT SCIENCES CORP reported revenue of $3.2B.
Does EXAS pay dividends?
EXACT SCIENCES CORP does not currently pay dividends.
Where can I find EXAS SEC filings?
Official SEC filings for EXACT SCIENCES CORP (CIK: 0001124140) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EXAS's EPS?
EXACT SCIENCES CORP has a diluted EPS of $-1.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EXAS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, EXACT SCIENCES CORP has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EXAS stock overvalued or undervalued?
Valuation metrics for EXAS: ROE of -8.7% (sector avg: 15%), net margin of -6.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EXAS stock in 2026?
Our dual AI analysis gives EXACT SCIENCES CORP a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EXAS's free cash flow?
EXACT SCIENCES CORP's operating cash flow is $491.4M, with capital expenditures of $134.7M. FCF margin is 11.0%.
How does EXAS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6.4% (avg: 12%), ROE -8.7% (avg: 15%), current ratio 2.43 (avg: 2).